News >

CLL Treatment Paradigm Expands Toward Novel Combo Regimens

Jessica Hergert
Published: Thursday, Mar 05, 2020

Bruce G. Raphael, MD, site director for NYU Langone Health Perlmutter Cancer Center

Bruce G. Raphael, MD

Following intriguing clinical activity with BTK inhibitors alone and in combination, and BCL-2 inhibitors added to CD20-directed agents, standard practice is moving away from chemotherapy and looking ahead to triplet regimens, explained Bruce G. Raphael, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication